NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Forecast, Price & News $45.67 -0.22 (-0.48%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$45.55▼$46.3550-Day Range$35.77▼$46.7052-Week Range$26.76▼$46.86Volume310,270 shsAverage Volume333,225 shsMarket Capitalization$2.20 billionP/E Ratio25.51Dividend YieldN/APrice Target$40.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amphastar Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside12.4% Downside$40.00 Price TargetShort InterestBearish5.32% of Float Sold ShortDividend StrengthN/ASustainability-2.21Upright™ Environmental ScoreNews Sentiment0.27Based on 9 Articles This WeekInsider TradingSelling Shares$4.92 M Sold Last QuarterProj. Earnings Growth4.65%From $2.15 to $2.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector560th out of 986 stocksPharmaceutical Preparations Industry266th out of 479 stocks 1.5 Analyst's Opinion Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, Amphastar Pharmaceuticals has a forecasted downside of 12.4% from its current price of $45.67.Amount of Analyst CoverageAmphastar Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.32% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently increased by 2.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.Environmental SustainabilityThe Environmental Impact score for Amphastar Pharmaceuticals is -2.21. Previous Next 2.4 News and Social Media Coverage News SentimentAmphastar Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows6 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,921,821.00 in company stock.Percentage Held by Insiders28.40% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 4.65% in the coming year, from $2.15 to $2.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 25.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 25.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.28.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amphastar Pharmaceuticals (NASDAQ:AMPH) StockAmphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.Read More Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMPH Stock News HeadlinesJune 8, 2023 | finance.yahoo.comHere is Why Growth Investors Should Buy Amphastar (AMPH) NowJune 8, 2023 | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO Sells $509,850.00 in StockJune 9, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...June 8, 2023 | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $750,888.58 in StockJune 2, 2023 | finance.yahoo.com4 Solid Profitable Stocks to Invest in Using Net Income RatioJune 1, 2023 | finance.yahoo.comIBD 50 Stock Hits All-Time High, And 44% EPS Growth ExpectedMay 28, 2023 | finance.yahoo.comAmphastar Pharmaceuticals (NASDAQ:AMPH) shareholders have earned a 22% CAGR over the last five yearsMay 25, 2023 | americanbankingnews.comWilliam J. Peters Sells 10,500 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) StockJune 9, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 23, 2023 | finance.yahoo.comLooking for a Growth Stock? 3 Reasons Why Amphastar (AMPH) is a Solid ChoiceMay 22, 2023 | msn.comAmphastar (AMPH) Is a Great Choice for 'Trend' Investors, Here's WhyMay 22, 2023 | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Sells $442,000.00 in StockMay 20, 2023 | americanbankingnews.comFloyd F. Petersen Sells 5,000 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) StockMay 19, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Amphastar Pharmaceuticals (NASDAQ:AMPH)May 18, 2023 | americanbankingnews.comRichard K. Prins Sells 5,000 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) StockMay 17, 2023 | msn.comWells Fargo Maintains Amphastar Pharmaceuticals (AMPH) Equal-Weight RecommendationMay 17, 2023 | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $316,350.00 in StockMay 12, 2023 | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Up 29.2% in AprilMay 11, 2023 | finance.yahoo.comAmphastar Pharmaceuticals First Quarter 2023 Earnings: EPS: US$0.54 (vs US$0.50 in 1Q 2022)May 10, 2023 | finance.yahoo.comQ1 2023 Amphastar Pharmaceuticals Inc Earnings CallMay 9, 2023 | finance.yahoo.comAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023May 9, 2023 | finance.yahoo.comAmphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue EstimatesMay 9, 2023 | americanbankingnews.comAnalysts Issue Forecasts for Amphastar Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:AMPH)May 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Protagonist Therapeutics (PTGX) and Amneal Pharmaceuticals (AMRX)May 8, 2023 | seekingalpha.comAmphastar Pharmaceuticals (AMPH) Presents At 22nd Annual Needham Virtual Healthcare Conference - SlideshowMay 7, 2023 | americanbankingnews.comAmphastar Pharmaceuticals (AMPH) to Release Earnings on TuesdayMay 5, 2023 | marketwatch.comNaloxone Market Outlook and Forecast till 2030See More Headlines AMPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPH Company Calendar Last Earnings11/08/2021Today6/09/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMPH CUSIPN/A CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,615Year FoundedN/APrice Target and Rating Average Stock Price Forecast$40.00 High Stock Price Forecast$44.00 Low Stock Price Forecast$36.00 Forecasted Upside/Downside-12.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.79 Trailing P/E Ratio25.51 Forward P/E Ratio21.24 P/E GrowthN/ANet Income$91.39 million Net Margins17.96% Pretax Margin23.25% Return on Equity18.37% Return on Assets12.89% Debt Debt-to-Equity Ratio0.13 Current Ratio3.86 Quick Ratio2.88 Sales & Book Value Annual Sales$498.99 million Price / Sales4.42 Cash Flow$2.35 per share Price / Cash Flow19.41 Book Value$10.94 per share Price / Book4.17Miscellaneous Outstanding Shares48,270,000Free Float34,561,000Market Cap$2.20 billion OptionableOptionable Beta0.77 Key ExecutivesZi Ping LuoChairman, COO & Chief ScientistYong Feng ZhangPresident, Chief Executive Officer & DirectorWilliam J. PetersChief Financial Officer, Treasurer, Director & EVPTony MarrsEVP-Regulatory Affairs & Clinical OperationsJacob LiawatidewiSecretary, Director, EVP-Sales & MarketingKey CompetitorsCureVacNASDAQ:CVACHarmony BiosciencesNASDAQ:HRMYHUTCHMEDNASDAQ:HCMMirati TherapeuticsNASDAQ:MRTXCorcept TherapeuticsNASDAQ:CORTView All CompetitorsInsiders & InstitutionsWilliam J PetersSold 11,000 sharesTotal: $509,850.00 ($46.35/share)Howard LeeSold 16,679 sharesTotal: $750,888.58 ($45.02/share)ProShare Advisors LLCSold 1,136 shares on 5/26/2023Ownership: 0.018%Royce & Associates LPBought 22,315 shares on 5/23/2023Ownership: 0.046%Capital Impact Advisors LLCBought 635 shares on 5/23/2023Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions AMPH Stock - Frequently Asked Questions Should I buy or sell Amphastar Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMPH shares. View AMPH analyst ratings or view top-rated stocks. What is Amphastar Pharmaceuticals' stock price forecast for 2023? 3 Wall Street analysts have issued 12 month price targets for Amphastar Pharmaceuticals' shares. Their AMPH share price forecasts range from $36.00 to $44.00. On average, they expect the company's stock price to reach $40.00 in the next year. This suggests that the stock has a possible downside of 12.8%. View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts. How have AMPH shares performed in 2023? Amphastar Pharmaceuticals' stock was trading at $28.02 at the beginning of 2023. Since then, AMPH stock has increased by 63.8% and is now trading at $45.89. View the best growth stocks for 2023 here. When is Amphastar Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our AMPH earnings forecast. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its earnings results on Monday, November, 8th. The company reported $0.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.22. The company earned $112.20 million during the quarter, compared to analysts' expectations of $103 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 18.37% and a net margin of 17.96%. During the same period last year, the business posted $0.09 earnings per share. What ETFs hold Amphastar Pharmaceuticals' stock? ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Janus Henderson Small Cap Growth Alpha ETF (JSML), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap Health Care ETF (PSCH), First Trust Active Factor Small Cap ETF (AFSM), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) and ERShares NextGen Entrepreneurs ETF (ERSX). What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO? 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT). What is Amphastar Pharmaceuticals' stock symbol? Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH." Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.63%), Federated Hermes Inc. (7.03%), Dimensional Fund Advisors LP (3.98%), State Street Corp (2.82%), Geode Capital Management LLC (1.57%) and Granite Investment Partners LLC (1.11%). Insiders that own company stock include David Maris, Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amphastar Pharmaceuticals' stock price today? One share of AMPH stock can currently be purchased for approximately $45.89. How much money does Amphastar Pharmaceuticals make? Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $2.22 billion and generates $518.64 million in revenue each year. The company earns $91.39 million in net income (profit) each year or $1.79 on an earnings per share basis. How many employees does Amphastar Pharmaceuticals have? The company employs 1,615 workers across the globe. How can I contact Amphastar Pharmaceuticals? Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at jasons@amphastar.com, or via fax at 909-980-8296. This page (NASDAQ:AMPH) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.